Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk

Takeda walks away from cell therapy in priority U-turn

Taysha Says FDA Grants Breakthrough Therapy Designation To In Rett Syndrome

Intravitreal Injection of Retinal Progenitor Cells Shows Promise in Preclinical Study for Diabetic Retinopathy

Mercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein